Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Prospective Randomized Phase II Trial of Pazopanib (NSC # 737754) Versus Placebo in Patients With Progressive Carcinoid Tumors

Trial Profile

Prospective Randomized Phase II Trial of Pazopanib (NSC # 737754) Versus Placebo in Patients With Progressive Carcinoid Tumors

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 08 Jul 2019

At a glance

  • Drugs Pazopanib (Primary)
  • Indications Carcinoid tumour; Neuroendocrine carcinoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 04 Jun 2019 Primary endpoint (Progression-free survival (PFS)) has been met as per results presented at the 55th Annual Meeting of the American Society of Clinical Oncology
    • 04 Jun 2019 Results presented at the 55th Annual Meeting of the American Society of Clinical Oncology
    • 12 Dec 2018 Planned primary completion date changed from 1 Feb 2019 to 1 Jun 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top